Actithera
What They Do
Radiopharmaceutical company developing radioligand therapies for cancer treatment. Radioligand therapy targets cancer cells with radioactive compounds, offering precision treatment with fewer side effects than traditional chemotherapy.[1]
Revenue
Org nr: 935 938 341 Source: proff.no
- 2024: N/A (no accounts filed)
- Employees: 1-4
Founded May 2025. Radiopharmaceutical company developing radioligand therapies for cancer. Norwegian subsidiary of Actithera Group AS. US operations. $75.5M Series A (Jul 2025).
Funding
$75.5 million Series A (July 2025).[2]
Notably, Actithera secured this large Series A without a complete leadership team in place — defying typical VC expectations.[3] BioPharma Dive reported the company drew "new investors to radiopharma drug pitch."[4]
European Biotechnology Magazine noted the deal reflects "huge momentum" in radiopharma funding globally.[5]
See Also
- ↑ pharmaphorum (Jul 2025): "New radiopharma Actithera emerges with $75.5m in financing"
- ↑ ArcticStartup (Jul 10, 2025): "Norway & US-based Actithera raises $75.5M Series A to advance radioligand therapy pipeline"
- ↑ BioXconomy (2025): "Defying Series A odds: How Actithera secured $75.5m without a leadership team"
- ↑ BioPharma Dive (2025): "Actithera draws new investors to radiopharma drug pitch"
- ↑ European Biotechnology Magazine (2025): "Actithera: Radiopharma Funding Gathers Huge Momentum"